Showing 1161-1170 of 1308 results for "".
- Sight Sciences Appoints Erica Rogers to its Board of Directorshttps://modernod.com/news/sight-sciences-appoints-erica-rogers-to-its-board-of-directors/2477149/Sight Sciences announced the appointment of Erica Rogers to the company’s board of directors. Ms. Rogers, President and CEO of Silk Road Medical, is an experienced leader and entrepreneur in the medical device industry. She most recently led Silk Road Medical through FDA approval of
- Fight For Sight and Prevent Blindness Announce Call for Entries for the 2020 Joanne Angle Public Health Awardhttps://modernod.com/news/fight-for-sight-and-prevent-blindness-announce-call-for-entries-for-the-2020-joanne-angle-public-health-award/2476933/National non-profit organizations Fight for Sight and Prevent Blindness are announcing a call for applications for the Joanne Angle Public Health Award, a $25,000 grant to support a public health research project seeking to put an end to unnecessary vision loss. The award was named for Ms
- Foundation Fighting Blindness Appoints Judy Taylor Vice President, Developmenthttps://modernod.com/news/foundation-fighting-blindness-appoints-judy-taylor-vice-president-development/2476733/The Foundation Fighting Blindness has announced that it has appointed Judy Taylor as vice president, development. In her new role, Ms. Taylor will be responsible and accountable for the strategic direction, planning and oversight of major gifts and planned giving function for the foundation.
- Allegro Ophthalmics Appoints Marc Carlson and Rebecca Colbert to Board of Directorshttps://modernod.com/news/allegro-ophthalmics-appoints-marc-carlson-and-rebecca-colbert-to-board-of-directors/2476454/Allegro Ophthalmics announced that two new independent members—Marc Carlson and Rebecca Colbert—have been appointed to the company’s Board of Directors with Ms. Colbert serving as Chairperson of the Board’s Audit Committee. Bringing extensive executive level commercial and financial leadership ex
- Lilliana Vazquez to Moderate Vision Expo’s EYE2EYE Series with Commonhttps://modernod.com/news/lilliana-vazquez-to-moderate-vision-expos-eye2eye-series-with-common/2476392/Vision Expo has announced Lilliana Vazquez will moderate its inaugural EYE2EYE series with award-winning artist Common. Ms. Vazquez is a multi-media personality that has acted as a host, influencer, style advisor and producer for the biggest names in entertainment, including working as a contribu
- Ophthalmic World Leaders (OWL) Names First MD President and Other Leadership Changes for 2026https://modernod.com/news/ophthalmic-world-leaders-owl-names-first-md-president-and-other-leadership-changes-for-2026/2484293/Ophthalmic World Leaders (OWL) announces the appointment of Renee Bovelle, MD, as its new President. OWL also welcomes three new members to its Board of Directors: Kevin M. Douglas, MD (Medical Director, Eye Care – Retina, AbbVie), Maáza Martin (S
- Tilak Receives Positive Opinion in Europe for Early Reimbursement of Odysight Telemonitoring Devicehttps://modernod.com/news/tilak-receives-positive-opinion-for-early-reimbursement-of-odysight-telemonitoring-device/2484169/Paris-based Tilak Healthcare has received a positive opinion from the French National Health Authority (Haute Autorité de Santé, HAS) for the reimbursement of Odysight under the PECAN (Prise En Charge Anticipée des dispositifs m&
- Bausch + Lomb Launches Lumify Preservative Free Redness Reliever Eye Drops in the UShttps://modernod.com/news/bausch-lomb-launches-lumify-preservative-free-redness-reliever-eye-drops-in-the-united-states/2482814/Bausch + Lomb announced the US launch of Lumify Preservative Free redness reliever eye drops, which the company describes as the first and only preservative-free over-the-counter (OTC) eye drops with low-dose brimonidine tartrate 0.025% that relieve redness of the eye due to m
- Sydnexis Announces Positive CHMP Opinion in Europe for Myopia Drug Candidate SYD-101https://modernod.com/news/sydnexis-announces-positive-chmp-opinion-in-europe-for-myopia-drug-candidate-syd-101/2482722/Sydnexis announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for its proprietary low-dose atropine formulation, SYD-101, for slowing the progression of pediatric m
- PulseSight Therapeutics Initiates Clinical Plan of PST-611 Transferrin Vectorized Therapy for Dry AMD/GAhttps://modernod.com/news/pulsesight-therapeutics-initiates-clinical-plan-of-pst-611-transferrin-vectorized-therapy-for-dry-amdga/2482615/PulseSight Therapeutics SAS announced it has submitted a clinical trial authorization (CTA) to Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) for a phase 1 trial (PST-611-CT1) assessing the safety